When Lilly announced TRIUMPH-2 topline results back in July, we covered the headline: up to 20.8% weight loss in a type 2 diabetes population, which was strong enough to raise eyebrows. Topline numbers are useful but incomplete. They tell you a trial succeeded without telling you much about who dropped out, at what doses, and what the trade-offs looked like in practice.
That changed this month. The full peer-reviewed paper was published in the Lancet on 10 October, presented at the EASD meeting in Milan alongside the simultaneous publication, and it fills in the picture the press release left out.
What the trial was
TRIUMPH-2 randomised 1,152 adults with obesity or overweight and type 2 diabetes, one-to-one-to-one-to-one, to placebo or once-weekly retatrutide at 4 mg, 9 mg or 12 mg. Participants started at a lower dose and stepped up every four weeks to their target dose over the titration period. The primary endpoint was the percentage change in body weight at 80 weeks for the 9 mg and 12 mg doses against placebo, with the 4 mg dose as a key secondary endpoint. The average starting body weight was about 106 kg.
The paper’s lead author is Virginia Bellido, and the trial is registered as NCT05929079. Our previous coverage of the topline results is here, and the retatrutide research page carries the full programme history.
What the Research Says
- For the treatment-regimen estimand, the mean percentage change in body weight at 80 weeks was -11.9% with retatrutide 4 mg, -16.8% with 9 mg, -18.8% with 12 mg, and -5.1% with placebo, all statistically significant versus placebo.
- Lilly’s separately reported efficacy estimand figures, which assume participants stayed on treatment without new diabetes medication, were higher: up to 20.8% at 12 mg, with A1C reductions of up to 1.6 percentage points and up to 40.0% of participants reaching an A1C below 5.7%, which is the non-diabetic range.
- Permanent treatment discontinuation due to adverse events or death was more frequent with retatrutide 9 mg (12%) and 12 mg (8%) compared with 4 mg (4%) and placebo (5%).
- The dose-response relationship is consistent across the programme: more retatrutide means more weight loss and more discontinuation, in roughly equal measure.
Why the estimand distinction matters more than usual
The Lancet paper reports two estimands, and the gap between them is genuinely informative. The treatment-regimen estimand reflects what happened to everyone assigned to a dose, including people who stopped early. The efficacy estimand reflects what happened to people who stayed on treatment.
The difference between the two at the 12 mg dose, 18.8% versus 20.8%, is about two percentage points. That gap is the footprint of the people who left. It is a smaller gap than some compounds in this class show, which is worth noting, but it is not nothing, and it is the honest number for anyone thinking about what the results mean for a population rather than a compliant subgroup.
The discontinuation data is the more interesting read. The 9 mg dose showing a higher discontinuation rate than the 12 mg dose is an odd-looking result, but it is a reminder that dose titration is not linear: some people tolerate their target dose fine and some do not, and the pattern does not follow the dose scale cleanly. The 12% figure at 9 mg means roughly one in eight participants on that dose quit for tolerability reasons, which is a real number that the topline announcement did not lead with.
Where this leaves the retatrutide picture
With the full TRIUMPH-2 paper published, retatrutide now has peer-reviewed phase 3 data in two populations: obesity without diabetes (TRIUMPH-1) and obesity with type 2 diabetes (TRIUMPH-2). The consistency of the dose-response relationship across both trials, and the similar discontinuation pattern, suggests the tolerability profile is a property of the compound rather than a feature of one population.
Lilly has guided toward a regulatory filing in the first quarter of 2027, which would set up approval decisions during 2027 if the timeline holds. Until then, retatrutide remains investigational everywhere, including Australia, where the TGA has not received or assessed an application for the compound. The grey-market reality is that retatrutide is already widely sold online as a research-use-only product, which is exactly the market segment the TGA and counterfeit-product warnings target, and none of those products have any regulatory assurance behind them.
What it means for the community
For anyone tracking the incretin landscape, TRIUMPH-2 is now the reference dataset for what a triple agonist does in type 2 diabetes, and the Lancet publication means the numbers are citable rather than corporate. The comparison people in the community keep reaching for is against tirzepatide in the SURPASS programme, and the honest read is that retatrutide’s weight numbers are higher while the tolerability burden is correspondingly heavier. Our tirzepatide page and semaglutide page cover the comparator datasets.
The Grey Highway Telegram group has an ongoing thread on the Lancet paper, including the subanalyses on body composition that we have not covered here yet.
Sources
Source: Bellido V, et al. “Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial”, The Lancet, Volume 408, Issue 10563, pages 1455-1472, 10 October 2026, DOI: 10.1016/S0140-6736(26)01861-1: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01861-1/fulltext
Source: Eli Lilly and Company, “Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes”, 29 September 2026: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight
Source: Drug Topics, “Retatrutide Delivers 20.8% Weight Loss in Adults With Type 2 Diabetes”, 9 October 2026: https://www.drugtopics.com/view/retatrutide-delivers-20-8-weight-loss-in-adults-with-type-2-diabetes
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.